Erica Hlavin Bell

TL;DR: In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.

TL;DR: Recent insights in the understanding of cancer lipid metabolism are summarized, the evidence linking SREBP-1 with PI3K/Akt signaling-controlled glycolysis and with Myc-regulated glutaminolysis to lipid metabolism is discussed, and potential drugs targeting the SRE BP-1- driven lipid metabolism as anti-cancer agents are discussed.

TL;DR: Analytical chemistry results of lipid components in glioma tissues from different research groups are discussed and the molecular mechanisms that link oncogenes with lipid programming, and identification of the key molecular targets and development of effective drugs to inhibit lipid metabolism in malignant gliomas are discussed.

TL;DR: The selective overexpression of the protein arginine methyltransferase PRMT5 is reported as a novel candidate theranostic target in glioblastoma, offering a preclinical justification for targetingPRMT5-driven oncogenic pathways in this deadly disease.

TL;DR: This is the first study, to the authors' knowledge, to validate the prognostic importance of MGMT promoter methylation in patients with grade II glioma treated with combined radiotherapy and temozolomide and highlights its potential prognostic value beyond IDH1/2 mutation status.